World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board
May 30, 2023 08:00 ET
|
Incannex Healthcare
Highlights: Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.Dr. Bill Richards is among the world’s best known psychedelic researchers and practitioners. He has...
Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market
May 17, 2023 08:15 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
May 16, 2023 11:37 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
Optimi Health Granted Natural Health Product Site Licence By Health Canada
May 10, 2023 08:45 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
Kaya, One of the Largest Vertical Cannabis Companies in the Caribbean, Introduces Psychedelic Mushroom Chocolate; Updates on Jamaica’s Legal Psilocybin Market
May 10, 2023 08:00 ET
|
NUGL, Inc.
KINGSTON, Jamaica and LOS ANGELES, May 10, 2023 (GLOBE NEWSWIRE) -- Kaya Group ("Kaya" or "the Company") (OTC: NUGL), the first medicinal Ganja herb house in the Caribbean and holistic,...
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
May 04, 2023 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a...
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
May 01, 2023 18:52 ET
|
PharmAla Biotech
CORTEXA TO BE THE LEADING SUPPLIER OF MDMA AND PSILOCYBIN IN AUSTRALIA VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is...
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
April 25, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (MDMA.CSE) is excited to have received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex...
Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
March 15, 2023 07:30 ET
|
Incannex Healthcare
Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit...
Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership
March 06, 2023 07:00 ET
|
Mindset Pharma Inc.
TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized,...